Coronavirus Disease 2019 (COVID-19) - Pipeline Review, H2 2020

July 2020 | 3207 pages | ID: C49A7A19162DEN
Global Markets Direct

Abstracts

Coronavirus Disease 2019 (COVID-19) - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Coronavirus Disease - Pipeline Review, H2 2020, provides an overview of the Coronavirus Disease (Infectious Disease) pipeline landscape.
Coronaviruses are a group of viruses belonging to the family Coronaviridae. These viruses cause respiratory infections ranging from the common cold to severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The most common symptoms are fever, tiredness, and dry cough. The virus is thought to spread mainly from person-to-person who are in close contact with one another and through respiratory droplets produced when an infected person coughs or sneezes.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Coronavirus Disease - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Coronavirus Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Coronavirus Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Coronavirus Disease 2019 (COVID-19) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 64, 121, 94, 4, 42, 288, 271 and 11 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages comprises 1, 7, 5, 1, 69, 69 and 2 molecules, respectively.
Coronavirus Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Coronavirus Disease (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Coronavirus Disease (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Coronavirus Disease (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Coronavirus Disease (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Coronavirus Disease (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Coronavirus Disease (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Coronavirus Disease (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Coronavirus Disease 2019 (COVID-19) - Overview
Coronavirus Disease 2019 (COVID-19) - Therapeutics Development
Coronavirus Disease 2019 (COVID-19) - Therapeutics Assessment
Coronavirus Disease 2019 (COVID-19) - Companies Involved in Therapeutics Development
Coronavirus Disease 2019 (COVID-19) - Drug Profiles
Coronavirus Disease 2019 (COVID-19) - Dormant Projects
Coronavirus Disease 2019 (COVID-19) - Discontinued Products
Coronavirus Disease 2019 (COVID-19) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Coronavirus Disease 2019 (COVID-19), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Coronavirus Disease 2019 (COVID-19) - Pipeline by 4D Pharma Plc, H2 2020
Coronavirus Disease 2019 (COVID-19) - Pipeline by A2A Pharmaceuticals Inc, H2 2020
Coronavirus Disease 2019 (COVID-19) - Pipeline by AB Science SA, H2 2020
Coronavirus Disease 2019 (COVID-19) - Pipeline by AbbVie Inc, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Coronavirus Disease 2019 (COVID-19), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

COMPANIES MENTIONED

4D Pharma Plc
A2A Pharmaceuticals Inc
AB Science SA
AbbVie Inc
Abivax SA
Abnova Corp
Aclaris Therapeutics Inc
Adaptive Biotechnologies Corp
Adjuvance Technologies Inc
Aerogen Ltd
Afecta Pharmaceuticals Inc
Agenus Inc
AI Therapeutics
AIkido Pharma Inc
AIM ImmunoTech Inc
AiVita Biomedical Inc
Akari Therapeutics Plc
Akebia Therapeutics Inc
Akers Biosciences Inc
Akshaya Bio Inc
Akston Biosciences Corp
Aldeyra Therapeutics Inc
Alexion Pharmaceuticals Inc
Alfasigma SpA
Algernon Pharmaceuticals Inc
AlloVir Inc
Alnylam Pharmaceuticals Inc
Alphamab Oncology
Altimmune Inc
Amarin Corp Plc
Amgen Inc
Ampio Pharmaceuticals Inc
AnGes Inc
Angion Biomedica Corp
Anixa Biosciences Inc
Ansun Biopharma Inc
AntiCancer Inc
APEIRON Biologics AG
Apellis Pharmaceuticals Inc
Apeptico Forschung und Entwicklung GmbH
Apogenix AG
Applied Therapeutics Inc
Aptorum Group Ltd
Arbutus Biopharma Corp
ARCA biopharma Inc
Arch Biopartners Inc
Arcturus Therapeutics Ltd
Argenx SE
Aridis Pharmaceuticals Inc